Planning to complete a deal soon?

We're putting the final touches to our webinar next Tuesday on the art of landing the best licensing deal for your biotech, and I'd like to ask the biotech execs who read our report to complete a quick and easy survey on your deal-making plans. We're trying to check the pulse on near-term deal activity, and it would be helpful for us if you could take a second to fill this out. You can take the survey here.

For those of you interested in hammering out the best deal possible for your biotech company, please join us at 2 p.m. EST October 27, when we'll gather together some of the industry's top dealmakers to review trends and strategies on landing a new pact. Ad Rawcliffe, SVP, Worldwide Business Development & Finance, GlaxoSmithKline, will join Anna Protopapas, SVP, Corporate Development & Strategy, Millennium Takeda and Geoff Meyerson and Jay Mohr from Locust Walk Partners. Mohr and Meyerson are completing a separate survey examining what pharma companies are looking for and where the money is for new deals. They'll review the results during the webinar. You can register here. I'll be joining the group as host. I hope to see you online. - John Carroll

Suggested Articles

Just weeks after the biotech raised a $63 million round, Accent Therapeutics is striking its first Big Pharma partnership with AstraZeneca.

Pliant Therapeutics will use the proceeds to push its lead program through midstage trials in fibrotic liver and lung diseases.

Cancer biotech Novellus has struck a deal with Plexxikon for its early- to midstage BRAF-inhibiting hopeful PLX8394.